Moderna (MRNA) 2025 revenue outlook of about USD 1.9bln (exp. USD 1.89bln) and improving 2025 expected GAAP operating expenses by USD 200mln to USD 5-5.2bln
Importance
Level 1
- Cash, cash equivalents and investments at year-end 2025 about USD 8.1bln.
- Expects GAAP operating expenses of USD 4.2-4.6bln in 2027, targeting cash breakeven in 2028.
- Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026.
- Potential first approvals of flu and flu/covid combination products in 2026.
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#MODERNA INC#MRNA#DXY#US EQUITIES